An open evaluation of triple antibiotic therapy including vancomycin for febrile bone marrow transplant recipients with severe neutropenia

Journal of Chemotherapy

Volumn 11, Issue 4, 1999, Pages 287-292

  Bosi, Alberto ^a,b   Laszlo, D ^a   Bacci, S ^a   Fanci, R ^a   Guidi, S ^a   Saccardi, R ^a   Vannucchi, A M ^a   Rossi Ferrini, P ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Amikacin; Bone marrow transplantation; Ceftazidime; Febrile neutropenia; Vancomycin

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; ITRACONAZOLE; METRONIDAZOLE; TEICOPLANIN; VANCOMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BONE MARROW TRANSPLANTATION; CHILD; DRUG EFFICACY; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT OUTCOME;

EID: 0032803053     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.4.287     Document Type: Article

References (32)

1. Sparrelid E, Hagglund H, Remberg M et al. Risk factors for septicemia during aplastic period after allogeneic bone marrow transplantation. Transp Proc 1995; 27: 3530.
2. Steiner M, Villablanca J, Kersey J et al. Alpha-streptococcal shock in bone marrow transplantation patients. Blood 1988; 72: (supp 1): 409A.
3. Klastersky J. Febrile neutropenia. Curr Opin Oncol 1993; 5: 625-632.
4. Hughes WT, Bodey GP, Feld R et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161: 381-396.
5. EORTC. International Antimicrobial Therapy Cooperative Group, NCI of Canada. Vancomycin added to empiric combination therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-958.
6. Joshi JH, Newman KA, Brown et al. Double beta-lactam regimen compared to an aminoglycoside/beta-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Supp Care Cancer 1993; 1: 186-194.
7. Laszlo D, Bacci S, Bosi A et al. Randomized trial comparing netilmicin plus imipenem versus netilmicin plus ceftazidime as empiric therapy in febrile neutropenic BMT recipients. J Chemother 1997; 9 : 95-101.
8. Menichetti F, Del Favero A. The role of gram-positive therapy in the neutropenic patient. J Antimicrob Chemother 1991; 27 (supp B): 51-60.
9. Menichetti F, Martino P, Bucaneve G, et al. Effects of teicoplanin and those of vancomycin as initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program. Antimicrob Agents Chemother 1994; 38 (9): 2041-2046.
10. Attal M, Schlaifer D, Rubie H et al. Prevention of gram-positive infections after bone marrow transplantation by systemic vancomycin: a prospective, randomized trial. J Clin Oncol 1991; 9 (5): 865-870.
11. Bosi A, Fanci R, Pecile P et al. Aztreonam versus colistin-neomycin for selective decontamination of the digestive tract in patients undergoing bone marrow transplantation: a randomized study. J Chemother 1992; 4: 30-34.
12. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporin compared with cyclosporin alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
13. Buggia I, Zecca M, Alessandrino EP et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di midollo Osseo). Anticancer Res 1996; 16 (4A): 2083-2088.
14. Schemeiser T, Ward HP, Clayton ML, et al. Application of antimicrobial prophylactic treatment to the prevention of infection and graft-versus-host disease in allogeneic bone marrow transplantation. Exp Hematol 1984; 12 (Suppl.15): 105-106.
15. Vossen JM, Heidt PJ. Gnotobiotic measures for the prevention of acute graft-vs-host disease. In: Burakoff SJ, Deeg HJ (eds). Graft-vs-host disease: Immunology, Pathophysiology and Treatment. New York: Marcel Dekker, 1990: 403-413.
16. Rozdzinski E, Kem WV, Reichle A et al. Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empiric therapy for febrile neutropenic patients. J Antimicrob Chemother 1993; 31(4): 585-598.
17. Martino P, Micozzi A, Gentile G et al. Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis. Clin Infect Dis 1992; 15: 290-294.
18. Viscoli C, Moroni C, Boni L et al. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis 1991; 13: 397-404.
19. Buckner CD, Clift RA, Thomas ED et al. Early infectious complications in allogeneic marrow transplant recipients with acute leukemia: effects of prophylactic measures. Infection 1983; 11: 243-250.
20. Henslee J, Bostrom B., Weisdorf D et al. Streptococcal sepsis in bone marrow transplant patients (letter). Lancet 1984; 1: 393.
21. Valteau D, Hartman O, Brugieres L et al. Streptococcal septicaemia following autologous bone marrow transplantation in children treated with high-dose chemotherapy. Bone Marrow Transplant 1991; 7: 415-419.
22. Koya R, Andersen J, Femandez H et al. Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. Bone Marrow Transplant 1998; 21: 923-926.
23. Engelhard D, Elishoov H, Or R et al. Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant 1995; 16: 565-570.
24. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14: 1201-1207.
25. Farber BF, Moellering JC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138-141.
26. Kureishi A, Jewesson PJ, Rubinger M et al. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients received concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Antimicrob Agents Chemother 1991; 35: 2246-2252.
27. Rubin M, Hathorn JW, Marshall D et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988; 108: 30-35.
28. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1988; 316: 927-931.
29. Mossad SB, Longworth DL, Goormastic M et al. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996; 18: 265-271.
30. Hughes WT, Armstrong D, Bodey GP et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25: 551-573.
31. Philpott NJ, Brownlee R., Morrison D et al. Vancomycin-resistant enterococci (VRE) on a leukemia/BMT Unit. Bone Marrow Transplant 1997; 1 (Suppl 19): O335.
32. Venditti M, Goglio A and the GIMEMA Microbiology Group. Vancomycin susceptibility in enterococcal blood isolates in Italy: a multicenter retrospective analysis. J Chemother 1996; 8: 33-36.